Skip to main content
. Author manuscript; available in PMC: 2019 Jan 1.
Published in final edited form as: Lancet Oncol. 2017 Nov 20;19(1):101–114. doi: 10.1016/S1470-2045(17)30694-0

Figure 2.

Figure 2

Figure 2

Co-primary endpoints, a) PFS in patients with EGFR-FISH+ cancers; b) OS in the entire study population